457 related articles for article (PubMed ID: 22249249)
1. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
Steele N; Finn P; Brown R; Plumb JA
Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
[TBL] [Abstract][Full Text] [Related]
3. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
[TBL] [Abstract][Full Text] [Related]
4. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.
Strathdee G; MacKean MJ; Illand M; Brown R
Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
6. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
7. Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line.
Alghamian Y; Soukkarieh C; Abbady AQ; Murad H
Sci Rep; 2022 May; 12(1):7494. PubMed ID: 35523936
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer.
Zhang YW; Zheng Y; Wang JZ; Lu XX; Wang Z; Chen LB; Guan XX; Tong JD
Epigenetics; 2014 Jun; 9(6):896-909. PubMed ID: 24699858
[TBL] [Abstract][Full Text] [Related]
9. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.
Fang F; Munck J; Tang J; Taverna P; Wang Y; Miller DF; Pilrose J; Choy G; Azab M; Pawelczak KS; VanderVere-Carozza P; Wagner M; Lyons J; Matei D; Turchi JJ; Nephew KP
Clin Cancer Res; 2014 Dec; 20(24):6504-16. PubMed ID: 25316809
[TBL] [Abstract][Full Text] [Related]
10. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
Mossman D; Kim KT; Scott RJ
BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
[TBL] [Abstract][Full Text] [Related]
11. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer.
Balch C; Yan P; Craft T; Young S; Skalnik DG; Huang TH; Nephew KP
Mol Cancer Ther; 2005 Oct; 4(10):1505-14. PubMed ID: 16227399
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I
Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589
[TBL] [Abstract][Full Text] [Related]
13. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
14. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
15. Mismatch repair and treatment resistance in ovarian cancer.
Helleman J; van Staveren IL; Dinjens WN; van Kuijk PF; Ritstier K; Ewing PC; van der Burg ME; Stoter G; Berns EM
BMC Cancer; 2006 Jul; 6():201. PubMed ID: 16879751
[TBL] [Abstract][Full Text] [Related]
16. Re-expression of methylation-induced tumor suppressor gene silencing is associated with the state of histone modification in gastric cancer cell lines.
Meng CF; Zhu XJ; Peng G; Dai DQ
World J Gastroenterol; 2007 Dec; 13(46):6166-71. PubMed ID: 18069755
[TBL] [Abstract][Full Text] [Related]
17. Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure.
Hesson LB; Patil V; Sloane MA; Nunez AC; Liu J; Pimanda JE; Ward RL
PLoS Genet; 2013; 9(7):e1003636. PubMed ID: 23935509
[TBL] [Abstract][Full Text] [Related]
18. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel PARP4 gene promoter CpG locus associated with cisplatin chemoresistance.
Sung HY; Han J; Chae YJ; Ju W; Lee Kang J; Park AK; Ahn JH
BMB Rep; 2023 Jun; 56(6):347-352. PubMed ID: 37013346
[TBL] [Abstract][Full Text] [Related]
20. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.
Solár P; Sytkowski AJ
Cancer Lett; 2011 Oct; 309(1):11-8. PubMed ID: 21676537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
